学习下核药(Pluvicto) 核药由载体(小分子、多肽、大分子等)、连接子和载体组成,更换螯合的核素可发挥不同作用,比如鳌合Ga-68(γ辐射)可肿瘤诊断,鳌合Lu-177(β辐射)可肿瘤治疗。 Pluvicto(lutetium Lu 177 vipivotide tetraxetan)结构式如下: Vipivotide tetraxetan (PSMA-617)可以结合到PSMA上,PSMA在80%以...
PSMAradioligand therapyFDG PET-CTcabazitaxelIn the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[ 177 Lu]Lu-PSMA-617 in post-...
药物别名 177Lu-PSMA-617 药效学 Lutetium Lu 177 vipivotide tetraxetan is a radioligand that exerts cytotoxic effects on cancer cells. Tumor uptake value is 11.2%ID/g. In clinical trials of patients with metastatic castration-resistant prostate cancer, treatment with lutetium Lu 177 vipivotide te...
PLUVICTO® lutetium Lu 177 vipivotide tetraxetan 是一款靶向肿瘤细胞表面PSMA(前列腺特异性膜抗原),进而释放放射性镥177(Lutetium-177)杀死肿瘤细胞的RDC核药。 药物由诺华公司开发,2022年获FDA批准上市,用于治疗去势抵抗型前列腺癌(mCRPC)成人患者。 药物国内尚未上市,根据英文名我暂称它为镥鲁177肽(音译无出处...
4/4,诺华公司周四确认,计划于 2024 年下半年申请其放射性配体药物 Pluvicto(lutetium 177 vipivotide tetraxetan)的标签扩展申请,旨在确保其在接受基于紫杉烷的化疗之前用于晚期前列腺癌患者。此次监管提交将基于 III 期 PSMAfore 研究的最新结果,该研究评估了 Pluvic
镥( 177 Lu) vipivotide tetraxetan,以品牌名称Pluvicto出售,是一种放射性药物,用于治疗前列腺特异性膜抗原(PSMA) 阳性的转移性去势抵抗性前列腺癌(mCRPC)。镥 ( 177 Lu) vipivotide tetraxetan 是一种靶向放射性配体疗法。 镥(177 Lu)vipivotide tetraxetan 于 2022 年 3 月在美国获批用于医疗用途,并于 202...
Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Based on 68Ga-PSMA-HBED-CC success, 177Lu-labelled PSMA ligands have peaked everyone's interest. This article discusses several articles on radionuclide treatments in prostate cancer and the initial results on 177Lu-PSMA therapy with either 177Lu-PSMA-617 or 177Lu-PSMA-I&T as a salvage ...
The patients randomized to the interventional arm will be eligible for two cycles of 7.4GBq 177 Lu-PSMA-I&T at a 6-week interval. After both cycles, patients are monitored every 3weeks (including adverse events, QoL- and xerostomia questionnaires and laboratory testing) at the outpatient ...
Prostate-specific membrane antigen (PSMA) theranostics has attracted increasing attention as a promising targeted treatment in metastatic prostate cancer (PC).Lu-DOTA-PSMA-617 (Lu-PSMA-617) is a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA ...